Track CRVO and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
CervoMed Inc.
20 Park Plaza, Boston, MA, United States, 02116
IPO
2016
Employees
15
Industry
Biotechnology
Sector
Healthcare
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20250+18
18
Analyst Ratings
2 analysts covering
Buy50%recommend buy
Buy
1
Hold
1
Sell
0